CDK4/6 inhibition in HER2-positive breast cancer

Affiliations

¹ Department of Medicine-Breast Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK. Electronic address: nicolo.battisti@rmh.nhs.uk.
² Department of Medicine-Breast Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK.

Comment

Nicolò Matteo Luca Battisti et al. Lancet Oncol. 2020 Jun.

. 2020 Jun;21(6):734-735.

doi: 10.1016/S1470-2045(20)30164-9. Epub 2020 Apr 27.

¹ Department of Medicine-Breast Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK. Electronic address: nicolo.battisti@rmh.nhs.uk.
² Department of Medicine-Breast Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK.

No abstract available

Comment on

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, Gainford MC, André F. Tolaney SM, et al. Lancet Oncol. 2020 Jun;21(6):763-775. doi: 10.1016/S1470-2045(20)30112-1. Epub 2020 Apr 27. Lancet Oncol. 2020. PMID: 32353342 Clinical Trial.